Targeting of the PERK/eIF2α pathway using the potent PERK inhibitor GSK2606414 [119,120] resulted in neuroprotection in prion disease and Tau-mediated frontotemporal dementia models. The gene discussed is EIF2AK3; the disease is prion disease.